Epileptic Syndromes clinical trials at University of California Health
2 research studies open to eligible people
Showing trials for
An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
open to eligible people ages 1 month to 6 years
To assess the long-term safety and tolerability of XEN496 in pediatric subjects with KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE) who had participated in the primary study (XPF-009-301).
at UCSF
XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
open to eligible people ages 1 month to 6 years
To investigate the potential antiseizure effects of adjunctive XEN496 (ezogabine) compared with placebo in children with KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE).
at UCSF
Last updated: